Loading clinical trials...
Loading clinical trials...
A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Tolerability of a Single Intravenous Infusion of BX-U001, a Human Umbilical Cord Tissue Derived Mesenchymal Stem Cell Product, for Refractory Rheumatoid Arthritis
Conditions
Interventions
hUC-MSC suspension
Placebo
Start Date
December 1, 2026
Primary Completion Date
December 31, 2027
Completion Date
February 20, 2028
Last Updated
December 23, 2025
NCT06647069
NCT07484243
NCT06841562
NCT07268326
NCT07233655
NCT07029555
Lead Sponsor
Baylx Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions